| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A706 | Prezalumab Featured | Prezalumab (AMG 557) is a monoclonal antibody targeting ICOSL that has synergistic anti-inflammatory activity with CD28 antibody inhibitors. |
|
| A707 | Enoblituzumab Featured | Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators. |
|
| A708 | Omburtamab Featured | Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research. |
|
| A709 | Trellis patent anti-B7-H3 Featured |
|
|
| A710 | Alsevalimab Featured | Alsevalimab is a human monoclonal antibody against B7-H4. |
|
| A711 | Millennium patent anti-B7-H4 Featured |
|
|
| A712 | Onvatilimab Featured | Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity. |
|
| A713 | Dartmouth patent anti-B7-H6 Featured |
|
|
| A714 | Genentech anti-BACE1 Featured |
|
|
| A715 | U.Toronto patent anti-Bax Featured |
|
|
| A716 | XmAb 5592 Featured | XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). |
|
| A717 | SBI Biotech patent anti-BST2 Featured |
|
|
| A718 | Icatolimab Featured |
|
|
| A719 | ICT-01 Featured |
|
|
| A720 | CTX-2026 Featured |
|
|
| A721 | ICT-01-N297A Featured |
|
|
| A722 | ANX005 Featured |
|
|
| A723 | Sutimlimab Featured | Sutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. |
|
| A725 | Eptinezumab Featured | Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults. |
|
| A726 | Galcanezumab Featured | Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research. |
|
| A727 | Fremanezumab Featured | Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research. |
|
| A728 | Erenumab Featured | Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine. |
|
| A729 | Toray patent anti-Caprin-1 Featured |
|
|
| A730 | Nimacimab Featured |
|
|
| A731 | GFB-024 Featured |
|
|
| A732 | Carlumab Featured | Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. |
|
| A733 | GSK-3050002 (E-6071) Featured |
|
|
| A734 | FG-3019 Featured | FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF). |
|
| A735 | Plozalizumab Featured | Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research. |
|
| A736 | Ivonescimab Featured | Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research. |
|
